In the VIKTORY umbrella GC trial36, treatment with pan-Akt inhibitor capivasertib + paclitaxel in patients with tumor expressing PIK3CA mutations resulted in 33.3% overall response rate (ORR). Here, AKT1 is linked to neoplasm.